<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858636</url>
  </required_header>
  <id_info>
    <org_study_id>CL06818</org_study_id>
    <nct_id>NCT01858636</nct_id>
  </id_info>
  <brief_title>Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device</brief_title>
  <acronym>SEAL PM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the clinical outcomes of Angio-Seal VIP with St. Jude Medical (SJM) collagen
      through the collection of device/procedure-related major vascular complications and time to
      hemostasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Subjects Experiencing a Device or Procedure Related Major Vascular Complication</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Major vascular complications include:
Access Site Complications:
Hematoma &gt;10 cm in size requiring surgical or percutaneous intervention
Major bleeding requiring transfusion of ≥2 units of blood or requiring surgical or percutaneous intervention
Pain requiring a hospitalization extended for more than 24 hours or a new hospitalization, or percutaneous or surgical intervention
Infection requiring a hospitalization extended for more than 24 hours or a new hospitalization or treatment with IV antibiotics
A/V Fistula requiring medical intervention (percutaneous or surgical)
Pseudoaneurysm requiring medical intervention (percutaneous or surgical) b. Lower Limb Ischemia requiring surgical or medical intervention or resulting in permanent injury/impairment c. Retroperitoneal hemorrhage requiring intervention (percutaneous or surgical)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Procedures Achieving Hemostasis Within 5 Minutes of Device Deployment.</measure>
    <time_frame>within 5 minutes of device deployment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">235</enrollment>
  <condition>Vascular Closure</condition>
  <arm_group>
    <arm_group_label>Angio-Seal VIP Vascular Closure</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angio-Seal VIP 6 French (6F) and 8 French (8F) devices</intervention_name>
    <description>These devices are used for the vascular closure procedure</description>
    <arm_group_label>Angio-Seal VIP Vascular Closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that will be included in the study will be indicated for the procedure according
        to the Instructions for Use. Physicians should carefully select patients based on the IFU
        including a consideration of all warnings and precautions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient requires closure of femoral artery puncture resulting from arterial access
             procedure.

          -  Patient is ≥18 years of age.

          -  Patient is willing to provide written informed consent prior to study device use.

          -  Patient is willing and able to adhere to data collection and follow-up requirements.

        Exclusion Criteria:

          -  Patient is participating in another clinical trial which has the potential to impact
             hemostasis.

          -  Patient has an active groin infection or systemic infection.

          -  Patient has undergone a vascular access procedure within the past 90 days.

          -  Patient has been previously enrolled in the study. (For patients undergoing multiple
             interventions within a timeframe of 90 days, only the initial procedure may constitute
             a study enrollment.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Diagnostiche und Interventionelle Radiologie</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GMBH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <results_first_submitted>October 24, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Angio-Seal VIP Vascular Closure</title>
          <description>Angio-Seal VIP 6 French (6F) and 8 French (8F) devices: These devices are used for the vascular closure procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="235">Subjects consented</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Device Deployment</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Device Deployment Attempted</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subects with deployed devices</population>
      <group_list>
        <group group_id="B1">
          <title>Angio-Seal VIP Vascular Closure</title>
          <description>Angio-Seal VIP 6F and 8F devices: These devices are used for the vascular closure procedure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Subjects Experiencing a Device or Procedure Related Major Vascular Complication</title>
        <description>Major vascular complications include:
Access Site Complications:
Hematoma &gt;10 cm in size requiring surgical or percutaneous intervention
Major bleeding requiring transfusion of ≥2 units of blood or requiring surgical or percutaneous intervention
Pain requiring a hospitalization extended for more than 24 hours or a new hospitalization, or percutaneous or surgical intervention
Infection requiring a hospitalization extended for more than 24 hours or a new hospitalization or treatment with IV antibiotics
A/V Fistula requiring medical intervention (percutaneous or surgical)
Pseudoaneurysm requiring medical intervention (percutaneous or surgical) b. Lower Limb Ischemia requiring surgical or medical intervention or resulting in permanent injury/impairment c. Retroperitoneal hemorrhage requiring intervention (percutaneous or surgical)</description>
        <time_frame>30 days post procedure</time_frame>
        <population>All subjects with device deployments.</population>
        <group_list>
          <group group_id="O1">
            <title>Deployed Subjects</title>
            <description>Percentage of subjects who experienced a major vascular complication during 30-days post procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects Experiencing a Device or Procedure Related Major Vascular Complication</title>
          <description>Major vascular complications include:
Access Site Complications:
Hematoma &gt;10 cm in size requiring surgical or percutaneous intervention
Major bleeding requiring transfusion of ≥2 units of blood or requiring surgical or percutaneous intervention
Pain requiring a hospitalization extended for more than 24 hours or a new hospitalization, or percutaneous or surgical intervention
Infection requiring a hospitalization extended for more than 24 hours or a new hospitalization or treatment with IV antibiotics
A/V Fistula requiring medical intervention (percutaneous or surgical)
Pseudoaneurysm requiring medical intervention (percutaneous or surgical) b. Lower Limb Ischemia requiring surgical or medical intervention or resulting in permanent injury/impairment c. Retroperitoneal hemorrhage requiring intervention (percutaneous or surgical)</description>
          <population>All subjects with device deployments.</population>
          <units>% of subjects with MVCs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" upper_limit="5.5">Per protocol, a one sided Fischer Exact test was performed. As a result, a lower confidence bound is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Ho: Pt ≥ 8% Ha: Pt &lt; 8%, where Pt is the proportion of deployed subjects with a protocol-defined vascular complication.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>Fisher Exact</method>
            <method_desc>A one-sided Fisher’s exact test was performed with a 95% upper confidence bound of 5.5%</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Procedures Achieving Hemostasis Within 5 Minutes of Device Deployment.</title>
        <time_frame>within 5 minutes of device deployment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deployed Subjects</title>
            <description>Subjects with Angio-Seal deployed</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Procedures Achieving Hemostasis Within 5 Minutes of Device Deployment.</title>
          <units>% of proc. w/hemostasis within 5 min</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="96.4">Per protocol, a one sided Fischer Exact test was performed. As a result an upper confidence bound is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Ho: St ≤ 90% Ha: St &gt; 90%, where St is the proportion of deployed subjects achieving hemostasis within 5 minutes.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <method_desc>A one-sided Fisher’s exact test was performed with a 95% lower confidence bound of 96.4%</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>A summary of all ADEs, Serious Adverse Events (SAEs), and non-serious vascular events</desc>
      <group_list>
        <group group_id="E1">
          <title>Deployed Subjects</title>
          <description>Adverse Events (AEs) are provided for all subjects that underwent a study device deployment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Decreased Left Ventricular Function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Elective Cardiac Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Sustained Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <description>Vascular Access Site Complication (VASC) Infections</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASC bleeding</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>VASC pseudoaneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Vascular Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Vascular Disection</sub_title>
                <description>Coronary Site - Not Access Site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Intracerebral Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VASC bruise</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>VASC hematoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>VASC bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="211"/>
              </event>
              <event>
                <sub_title>VASC pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Campbell</name_or_title>
      <organization>St. Jude Medical</organization>
      <phone>+1.651.756.5538</phone>
      <email>acampbell2@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

